Clinical implications of discordant viral and immune outcomes following protease inhibitor containing antiretroviral therapy for HIV-infected children

被引:0
|
作者
Carina A. Rodriguez
Sarah Koch
Maureen Goodenow
John W. Sleasman
机构
[1] University of South Florida,Department of Pediatrics, Division of Allergy, Immunology and Rheumatology
[2] College of Medicine,Division of Infectious Diseases
[3] All Children’s Hospital,Department of Pathology, Immunology, and Laboratory Medicine
[4] University of South Florida,undefined
[5] College of Medicine,undefined
[6] All Children’s Hospital,undefined
[7] University of Florida,undefined
[8] College of Medicine,undefined
来源
Immunologic Research | 2008年 / 40卷
关键词
HIV; Protease inhibitor; Thymus; Immune reconstitution; CD4 T cells;
D O I
暂无
中图分类号
学科分类号
摘要
Many HIV-infected children treated with protease inhibitors (PI) reconstitute immunity despite viral breakthrough predicting disease progression. We studied a unique cohort of PI treated children with advanced disease who demonstrated sustained CD4 T cell counts but median post therapy viral load rebounded to >4.0 log10 copies/ml. Phylogenetic relationships between pre- and post-therapy viruses reveals significant bottlenecks for quasispecies with natural polymorphisms mapping outside of protease active site providing selective advantage for emergence. Among discordant subjects post-therapy viruses fell into two phenotypes; high viral loads (median >5.0 log10 copies/ml) and attenuated post-therapy replication (median <4.0 log10 copies/ml). Both groups showed similar degrees of CD4 T cell immune reconstitution and were similar to children who optimally suppressed virus to <400 copies/ml. Both high fit and low fit discordant response groups showed high reconstitution of naïve CD4 CD45RA T cells (median 388 and 357 cells/μl, respectively). Naïve T cells increases suggest virus replicating under PI selective pressure do not impair thymic output. If therapeutic options are limited, selection of therapy which allows immune reconstitution despite suboptimal viral control may be beneficial. This novel paradigm for virus/host interactions may lead to therapeutic approaches to attenuate viral pathogenesis.
引用
收藏
页码:271 / 286
页数:15
相关论文
共 50 条
  • [41] Antiretroviral activity and safety of lopinavir/ritonavir in protease inhibitor-experienced HIV-infected children with severe-moderate immunodeficiency
    Resino, S
    Bellón, JM
    Muñoz-Fernández, MA
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2006, 57 (03) : 579 - 582
  • [42] Immune reconstitution inflammatory syndrome in HIV infected late presenters starting integrase inhibitor containing antiretroviral therapy
    Wijting, Ingeborg E. A.
    Wit, Ferdinand W. N. M.
    Rokx, Casper
    Leyten, Eliane M. S.
    Lowe, Selwyn H.
    Brinkman, Kees
    Bierman, Wouter F. W.
    van Kasteren, Marjo E. E.
    Postma, Anneloes M.
    Bloemen, Vera C. M.
    Bouchtoubi, Ghariba
    Hoepelman, Andy I. M.
    van der Ende, Marchina E.
    Reiss, Peter
    Rijnders, Bart J. A.
    ECLINICALMEDICINE, 2019, 17
  • [43] Immune reconstitution in HIV-1-infected children on antiretroviral therapy: role of thymic output and viral fitness
    Ometto, L
    De Forni, D
    Patiri, F
    Trouplin, V
    Mammano, F
    Giacomet, V
    Giaquinto, C
    Douek, D
    Koup, R
    De Rossi, A
    AIDS, 2002, 16 (06) : 839 - 849
  • [44] The impact of immune checkpoint therapy on the latent reservoir in HIV-infected individuals with cancer on antiretroviral therapy
    Lau, Jillian S. Y.
    McMahon, James H.
    Gubser, Celine
    Solomon, Ajantha
    Chiu, Chris Y. H.
    Dantanarayana, Ashanti
    Chea, Socheata
    Tennakoon, Surekha
    Zerbato, Jennifer M.
    Garlick, Jill
    Morcilla, Vincent
    Palmer, Sarah
    Lewin, Sharon R.
    Rasmussen, Thomas A.
    AIDS, 2021, 35 (10) : 1631 - 1636
  • [45] Hospitalization for severe malnutrition among HIV-infected children starting antiretroviral therapy
    Prendergast, Andrew
    Bwakura-Dangarembizi, Mutsa F.
    Cook, Adrian D.
    Bakeera-Kitaka, Sabrina
    Natukunda, Eva
    Ntege, Patricia Nahirya
    Nathoo, Kusum J.
    Karungi, Christine
    Lutaakome, Joseph
    Kekitiinwa, Adeodata
    Gibb, Diana M.
    AIDS, 2011, 25 (07) : 951 - 956
  • [46] Safety and Tolerability of Antiretroviral Therapy Among HIV-Infected Children And Adolescents In UGANDA
    Tukei, Vincent J.
    Asiimwe, Alice
    Maganda, Albert
    Atugonza, Rita
    Sebuliba, Isaac
    Bakeera-Kitaka, Sabrina
    Musoke, Phillipa
    Kalyesubula, Israel
    Kekitiinwa, Adeodata
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2012, 59 (03) : 274 - 280
  • [47] Hospitalization trends, costs, and risk factors in HIV-infected children on antiretroviral therapy
    Collins, Intira J.
    Cairns, John
    Jourdain, Gonzague
    Fregonese, Federica
    Nantarukchaikul, Maneeratn
    Lertpienthum, Narong
    Wannarit, Pornpun
    Attavinijtrakarn, Pornsawan
    Layangool, Prapaisri
    Le Coeur, Sophie
    Lallemant, Marc
    AIDS, 2012, 26 (15) : 1943 - 1952
  • [48] Blood Lactate in HIV-infected Children on Antiretroviral Therapy in Rural South Africa
    van Ramshorst, Mette S.
    Struthers, Helen E.
    Mcintyre, James A.
    Peters, Remco P. H.
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2014, 33 (04) : 393 - 395
  • [49] MEASLES OUTBREAK IN AN ORPHANAGE HIV-INFECTED CHILDREN ON ANTIRETROVIRAL THERAPY ARE STILL AT RISK
    Aurpibul, Linda
    Puthanakit, Thanyawee
    Kanjanavanit, Suparat
    Sirisanthana, Thira
    Sirisanthana, Virat
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2010, 29 (02) : 167 - 169
  • [50] Long-term clinical, virological and immunological outcomes following planned treatment interruption in HIV-infected children
    Freguja, R.
    Bamford, A.
    Zanchetta, M.
    Del Bianco, P.
    Giaquinto, C.
    Harper, L.
    Dalzini, A.
    Cressey, T. R.
    Compagnucci, A.
    Saidi, Y.
    Riault, Y.
    Ford, D.
    Gibb, D.
    Klein, N.
    De Rossi, A.
    HIV MEDICINE, 2021, 22 (03) : 172 - 184